PE20142399A1 - Compuestos de pirazol como inhibidores de sglt1 - Google Patents

Compuestos de pirazol como inhibidores de sglt1

Info

Publication number
PE20142399A1
PE20142399A1 PE2014001716A PE2014001716A PE20142399A1 PE 20142399 A1 PE20142399 A1 PE 20142399A1 PE 2014001716 A PE2014001716 A PE 2014001716A PE 2014001716 A PE2014001716 A PE 2014001716A PE 20142399 A1 PE20142399 A1 PE 20142399A1
Authority
PE
Peru
Prior art keywords
sglt1 inhibitors
compounds
pirazole
pirazole compounds
diazaespiro
Prior art date
Application number
PE2014001716A
Other languages
English (en)
Spanish (es)
Inventor
Fucheng Qu
Nathan Bryan Mantlo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20142399A1 publication Critical patent/PE20142399A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2014001716A 2012-05-10 2013-05-02 Compuestos de pirazol como inhibidores de sglt1 PE20142399A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645101P 2012-05-10 2012-05-10
US201361769221P 2013-02-26 2013-02-26

Publications (1)

Publication Number Publication Date
PE20142399A1 true PE20142399A1 (es) 2015-01-22

Family

ID=48428684

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001716A PE20142399A1 (es) 2012-05-10 2013-05-02 Compuestos de pirazol como inhibidores de sglt1

Country Status (42)

Country Link
US (2) US8697849B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2850084B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6148725B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101685779B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP3593A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR090806A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013259946B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014026198B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2869323C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014002845A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7141429A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20140473A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1117912T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2850084T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2014000250A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA024207B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP14026088A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2588835T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT201400242A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20160804T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE030414T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL235427A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN07996A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO3136B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2850084T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA37501B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME02405B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX357058B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY177326A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ700356A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20142399A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014502492B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2850084T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2850084T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS55107B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201407345QA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2850084T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TN2014000410A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI579295B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA113086C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013169546A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201407531B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
AR097890A1 (es) 2013-10-17 2016-04-20 Lilly Co Eli Compuestos de urea
AR098134A1 (es) 2013-11-01 2016-05-04 Lilly Co Eli Compuestos de urea
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法
IL277686B2 (en) * 2018-04-04 2024-11-01 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
WO2021045159A1 (ja) * 2019-09-04 2021-03-11 日本たばこ産業株式会社 併用医薬による糖尿病の治療又は予防方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
CA2438593C (en) 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
JP4399251B2 (ja) 2001-05-30 2010-01-13 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
BRPI0313290B1 (pt) * 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
RU2437876C2 (ru) * 2006-05-19 2011-12-27 Тайсо Фармасьютикал Ко., Лтд. Соединение с-фенилглицитола для лечения диабета
CA2709530C (en) 2007-12-27 2016-02-23 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
MX2011008839A (es) 2009-02-23 2011-09-28 Taisho Pharmaceutical Co Ltd Compuestos de 4-isopropilfenilglucitol como inhibidores de transportador de glucosa dependiente de sodio 1.
CN102753184A (zh) 2009-10-02 2012-10-24 赛诺菲 具有sglt-1/sglt-2抑制剂活性的化合物在制备用于治疗骨病的药物中的用途
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
US20140162967A1 (en) 2014-06-12
JP6148725B2 (ja) 2017-06-14
EA024207B1 (ru) 2016-08-31
MA37501A1 (fr) 2016-03-31
CY1117912T1 (el) 2017-05-17
LT2850084T (lt) 2016-09-12
AU2013259946A1 (en) 2014-10-16
PT2850084T (pt) 2016-08-02
ECSP14026088A (es) 2015-09-30
KR20150001798A (ko) 2015-01-06
BR112014026198A2 (pt) 2017-06-27
US9296775B2 (en) 2016-03-29
AP2014008044A0 (en) 2014-11-30
CL2014002845A1 (es) 2015-01-30
TW201406773A (zh) 2014-02-16
EA201491852A1 (ru) 2015-02-27
WO2013169546A1 (en) 2013-11-14
TWI579295B (zh) 2017-04-21
CO7141429A2 (es) 2014-12-12
AU2013259946B2 (en) 2015-09-10
US20130303471A1 (en) 2013-11-14
RS55107B1 (sr) 2016-12-30
PH12014502492A1 (en) 2015-01-12
AR090806A1 (es) 2014-12-10
EP2850084B1 (en) 2016-06-15
UA113086C2 (xx) 2016-12-12
DOP2014000250A (es) 2014-11-30
MA37501B1 (fr) 2016-11-30
GT201400242A (es) 2015-08-27
HUE030414T2 (en) 2017-05-29
IN2014DN07996A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-01
NZ700356A (en) 2016-06-24
HK1202542A1 (zh) 2015-10-02
KR101685779B1 (ko) 2016-12-12
PL2850084T3 (pl) 2017-05-31
EP2850084A1 (en) 2015-03-25
SG11201407345QA (en) 2014-12-30
JP2015516419A (ja) 2015-06-11
SI2850084T1 (sl) 2016-07-29
CA2869323A1 (en) 2013-11-14
CN104284894A (zh) 2015-01-14
US8697849B2 (en) 2014-04-15
ES2588835T3 (es) 2016-11-07
CA2869323C (en) 2016-03-29
MY177326A (en) 2020-09-11
ME02405B (me) 2016-09-20
AP3593A (en) 2016-02-15
IL235427A (en) 2016-06-30
ZA201407531B (en) 2016-05-25
PH12014502492B1 (en) 2015-01-12
BR112014026198B1 (pt) 2021-02-02
CR20140473A (es) 2014-11-21
JO3136B1 (ar) 2017-09-20
DK2850084T3 (en) 2016-09-12
MX357058B (es) 2018-06-25
CN104284894B (zh) 2016-02-17
MX2014013615A (es) 2015-02-12
TN2014000410A1 (en) 2015-12-21
HRP20160804T1 (hr) 2016-08-12

Similar Documents

Publication Publication Date Title
PE20142399A1 (es) Compuestos de pirazol como inhibidores de sglt1
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CO7180221A2 (es) Composiciones fungicidas
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CR20120296A (es) Nuevos compuestos de espiropiperidina
CO6670566A2 (es) Derivados de tetrahidro- pirido-pirimidina
PE20150224A1 (es) Inhibidores del nampt
NI201400043A (es) 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
EA201270216A1 (ru) Фармацевтический состав
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201591527A1 (ru) Новые производные пиридина
BR112015004111A2 (pt) novos derivados bicíclicos
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
GT201400111A (es) Triazolopiridinas sustituidas
PE20142359A1 (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
BR102013003576B8 (pt) Método para produzir n-ciano-s-metil-s-[1-(6-tri-flúormetil-3-piridinil)etil]sulfilimina
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
EA201391797A1 (ru) 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
MX360330B (es) Regimen de administracion para nitrocatecoles.
EA201270302A1 (ru) Безводные формы производных пиридина

Legal Events

Date Code Title Description
FG Grant, registration